MELINDA LAWHORN: Open Payments
NPI 1639719123 · GREENVILLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$991 in 45 payments from 20 companies in 2025. Trend: 2023 $1,087 · 2024 $1,054 · 2025 $991
Food & beverage: $991
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $249 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| AstraZeneca Pharmaceuticals LP | 5 | $89 |
| Novo Nordisk Inc | 3 | $70 |
| Madrigal Pharmaceuticals | 2 | $68 |
| Viatris Specialty LLC | 2 | $62 |
| Amgen Inc. | 2 | $44 |
| JAZZ PHARMACEUTICALS INC. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Boston Scientific Corporation | 1 | $29 |
Products named: VRAYLAR, REXULTI, REZDIFFRA, YUPELRI, Ozempic, BREZTRI, LINZESS, EVENITY.
Industry payments across TX — which companies pay providers there.
